The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Novel anti-BCMA immunotherapies have unprecedented responses
In this interview at the 23rd Congress of European Haematology Association (EHA) 2018, held in Stockholm, Sweden, Gareth Morgan, MD, PhD, FRCP, FRCPath, from the University of Arkansas for Medical Sciences, Little Rock, AR, talks about B-cell maturation antigen (BCMA) as the target for multiple CAR T-cell agents for relapsed/refractory multiple myeloma (MM). These agents are proving promising, with low toxicity and high tolerability; however, there are still improvements required, and Dr Morgan ponders if these could come with the GSK-916 antibody-drug conjugate directed against BCMA.
